Review the current literature and establish the level of evidence for a cutaneous melanoma 31-GEP test.

Multi center study establishing appropriate use criteria for determining risk of recurrence in patients with tumors >0.3mm in thickness

TissueCypher identifies NDBE patients who are at increased risk for progression to HGD/EAC and may benefit from increased surveillance or early intervention.

Independent, prospective study with over 3.5 years of follow-up, showing results consistent with previous validation studies with GEP class score as statistically associated with MSS, DMFS and RFS.

Clinical validation study of the 23-GEP in lesions with clinical outcomes and follow-up data

Multicentre evaluation the early prognostic performance of a genetic signature in a multicentre prospectively evaluated cohort.

Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method and both were independent predictors of recurrence in multivariate analysis.

Multicenter prospective study in T1-T2 tumors showed combining GEP with Breslow thickness and age can provide a more precise determination of SLN positivity risk.

Discovery of reduced RFS for patients with thin tumors and Class 2B biology and cumulative validation cohort for DecisionDx-Melanoma. DecisionDx-Melanoma was the strongest independent predictor of RFS, DMFS and MSS.

Independent study of the predictive accuracy of the GEP test, to determine what clinical and histopathologic features predict high-risk classification, and to evaluate how intermediate classes (1B & 2A) performed clinically. Patients with GEP Class 2 result were 22 times more likely to metastasize compared to a Class 1 result.

Survey to determine the impact of 31-GEP test results on management decisions made by dermatology PA/NPs for cutaneous melanoma patients.

Use of TissueCypher resulted in clinical “upstaging” occurred in 5 of 46 cases, leading to treatment that otherwise might not be pursued.